Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.62 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100971 | 0.92 | HRH3 (0.62) | HRH3S1PR5MAPTKDM4EALDH1A1 | |
| SCHEMBL21659367 | 0.84 | ESR2 (0.47) | HRH3S1PR5MAPTKDM4E | |
| SCHEMBL16268884 | 0.81 | PTGDR2 (0.52) | ALDH1A1 | |
| SCHEMBL14287565 | 0.81 | HRH3 (0.76) | HRH3 | |
| SCHEMBL5097381 | 0.81 | HRH3 (0.69) | HRH3 | |
| SCHEMBL6109296 | 0.80 | HRH3 (0.62) | HRH3MAPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14287594 | 0.79 | ABHD6 (0.55) | MAPTKDM4E | |
| SCHEMBL6110825 | 0.79 | HRH3 (0.61) | HRH3MAPTKDM4EALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6109294 | 0.79 | HRH3 (0.61) | HRH3MAPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5100586 | 0.78 | HRH3 (0.70) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | BEAVERS LISA SELSAM (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1379493-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002076925-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HRH3 1/4885S1PR5 467/4885MAPT 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.